Advertisement

Universal MRSA/Staphylococcal Decolonization for Hospitalized Patients

  • Edward J. Septimus
Chapter

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) remains an important public health threat. MRSA is one of the most important common causes of healthcare-associated infections (HAIs) in most hospitals. 47.9% of Staphylococcus aureus HAIs are due to MRSA. In addition, MRSA infections can result in substantial morbidity and mortality and lead it increase costs and length of stay. Both targeted decolonization, i.e. decolonization only patients identified to carry MRSA with chlorhexidine (CHG) bathing and intranasal mupirocin, and universal decolonization i.e. decolonize all high risk patients with CHG with or without mupirocin, have demonstrated decrease cross-transmission and infection with MRSA. Recent trials have shown that universal decolonization in adult and pediatric intensive care units (ICUs) have resulted in greater reduction of MRSA infections compared to targeted decolonization. Evidence for universal decolonization with CHG bathing in non-critical care is unresolved.

Keywords

Decolonization Methicillin resistance Staphylococcus aureus Healthcare-associated infections Mupirocin Chlorhexidine Active surveillance testing Vertical versus horizontal approaches 

References

  1. 1.
    Prevention CfDCa. Antibiotic resistance threats in the United States. 2013. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed 7 Mar 2016.
  2. 2.
    Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370:1198–208.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med. 2013;173:2039–46.CrossRefPubMedGoogle Scholar
  4. 4.
    Umscheid CA, Mitchell MD, Doshi JA, et al. Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs. Infect Control Hosp Epidemiol. 2011;32:101–14.CrossRefPubMedGoogle Scholar
  5. 5.
    Services. CfMaM. Medicare.gov HospitalCompare. http://www.medicare.gov/hospitalcompare/search.html. Accessed 5 Mar 2016.
  6. 6.
    Healthcare-Associated Infections – Healthy People. http://healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicId=17. Accessed 24 Jan 2016.
  7. 7.
    Weiner LM, Fridkin SK, Aponte-Torres Z, et al. Vital signs: preventing antibiotic-resistant infections in hospitals-United States, 2014. MMWR Morb Mortal Wkly Rep. 2016;65:235–41.CrossRefPubMedGoogle Scholar
  8. 8.
    Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol. 2005;26:166–74.CrossRefPubMedGoogle Scholar
  9. 9.
    den Heijer CD, van Bijnen EM, Paget WJ, et al. Prevalence and resistance of commensal Staphylococcus aureus, including meticillin-resistant S aureus, in nine European countries: a cross-sectional study. Lancet Infect Dis. 2013;13:409–15.CrossRefGoogle Scholar
  10. 10.
    Graham PL 3rd, Lin SX, Larson EL. A U.S. population-based survey of Staphylococcus aureus colonization. Ann Intern Med. 2006;144:318–25.CrossRefPubMedGoogle Scholar
  11. 11.
    Lim CJ, Cheng AC, Kennon J, et al. Prevalence of multidrug-resistant organisms and risk factors for carriage in long-term care facilities: a nested case-control study. J Antimicrob Chemother. 2014;69:1972–80.CrossRefPubMedGoogle Scholar
  12. 12.
    Evans ME, Kralovic SM, Simbartl LA, et al. Nationwide reduction of health care-associated methicillin-resistant Staphylococcus aureus infections in veterans affairs long-term care facilities. Am J Infect Control. 2014;42:60–2.CrossRefPubMedGoogle Scholar
  13. 13.
    Climo MW, Yokoe DS, Warren DK, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med. 2013;368:533–42.CrossRefPubMedGoogle Scholar
  14. 14.
    Wertheim HF, Melles DC, Vos MC, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis. 2005;5:751–62.CrossRefPubMedGoogle Scholar
  15. 15.
    VandenBergh MF, Yzerman EP, van Belkum A, et al. Follow-up of Staphylococcus aureus nasal carriage after 8 years: redefining the persistent carrier state. J Clin Microbiol. 1999;37:3133–40.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Nouwen JL, Fieren MW, Snijders S, et al. Persistent (not intermittent) nasal carriage of Staphylococcus aureus is the determinant of CPD-related infections. Kidney Int. 2005;67:1084–92.CrossRefPubMedGoogle Scholar
  17. 17.
    Nouwen JL, Ott A, Kluytmans-Vandenbergh MF, et al. Predicting the Staphylococcus aureus nasal carrier state: derivation and validation of a “culture rule”. Clin Infect Dis. 2004;39:806–11.CrossRefPubMedGoogle Scholar
  18. 18.
    Cheng VC, Li IW, Wu AK, et al. Effect of antibiotics on the bacterial load of meticillin-resistant Staphylococcus aureus colonisation in anterior nares. J Hosp Infect. 2008;70:27–34.CrossRefPubMedGoogle Scholar
  19. 19.
    Mermel LA, Cartony JM, Covington P, et al. Methicillin-resistant Staphylococcus aureus colonization at different body sites: a prospective, quantitative analysis. J Clin Microbiol. 2011;49:1119–21.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Sim BL, McBryde E, Street AC, Marshall C. Multiple site surveillance cultures as a predictor of methicillin-resistant Staphylococcus aureus infections. Infect Control Hosp Epidemiol. 2013;34:818–24.CrossRefPubMedGoogle Scholar
  21. 21.
    Bhalla A, Aron DC, Donskey CJ. Staphylococcus aureus intestinal colonization is associated with increased frequencu of S aureus on skin of hospitalized patients. BMC Infect Dis. 2007;7:105.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Schweizer M, Perencevich E, McDanel J, et al. Effectiveness of a bundled intervention of decolonization and prophylaxis to decrease Gram positive surgical site infections after cardiac or orthopedic surgery: systematic review and meta-analysis. BMJ. 2013;346:f2743.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Huang SS, Septimus E, Kleinman K, et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med. 2013;368:2255–65.CrossRefPubMedGoogle Scholar
  24. 24.
    Lee BY, Wiringa AE, Bailey RR, et al. Screening cardiac surgery patients for MRSA: an economic computer model. Am J Manag Care. 2010;16:e163–73.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Immerman I, Ramos NL, Katz GM, et al. The persistence of Staphylococcus aureus decolonization after mupirocin and topical chlorhexidine: implications for patients requiring multiple or delayed procedures. J Arthroplast. 2012;27:870–6.CrossRefGoogle Scholar
  26. 26.
    Loeb MB, Main C, Eady A, Walker-Dilks C. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev. 2003; doi: 10.1002/14651858.cd003340:CD003340.
  27. 27.
    Wenzel RP, Edmond MB. Infection control: the case for horizontal rather than vertical interventional programs. Int J Infect Dis. 2010;14(Suppl 4):S3–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Ward A, Campoli-Richards DM. Mupirocin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1986;32:425–44.CrossRefPubMedGoogle Scholar
  29. 29.
    Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 2002;346:1871–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Ammerlaan HS, Kluytmans JA, Wertheim HF, Nouwen JL, Bonten MJ. Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin Infect Dis. 2009;48:922–30.CrossRefPubMedGoogle Scholar
  31. 31.
    Tacconelli E, Carmeli Y, Aizer A, et al. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin Infect Dis. 2003;37:1629–38.CrossRefPubMedGoogle Scholar
  32. 32.
    van Rijen MM, Bonten M, Wenzel RP, Kluytmans JA. Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical patients with nasal carriage: a systematic review. J Antimicrob Chemother. 2008;61:254–61.CrossRefPubMedGoogle Scholar
  33. 33.
    Kallen AJ, Wilson CT, Larson RJ. Perioperative intranasal mupirocin for the prevention of surgical-site infections: systematic review of the literature and meta-analysis. Infect Control Hosp Epidemiol. 2005;26:916–22.CrossRefPubMedGoogle Scholar
  34. 34.
    van Rijen M, Bonten M, Wenzel R, Kluytmans J. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev. 2008; doi: 10.1002/14651858.CD006216.pub2:CD006216.
  35. 35.
    Mody L, Kauffman CA, McNeil SA, et al. Mupirocin-based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37:1467–74.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Perez-Fontan M, Rosales M, Rodriguez-Carmona A, et al. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis. 2002;39:337–41.CrossRefPubMedGoogle Scholar
  37. 37.
    Annigeri R, Conly J, Vas S, Dedier H, et al. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int J Int Soc Perit Dial. 2001;21:554–9.Google Scholar
  38. 38.
    Eltringham I. Mupirocin resistance and methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect. 1997;35:1–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Caffrey AR, Quilliam BJ, LaPlante KL. Risk factors associated with mupirocin resistance in meticillin-resistant Staphylococcus aureus. J Hosp Infect. 2010;76:206–10.CrossRefPubMedGoogle Scholar
  40. 40.
    Walker ES, Vasquez JE, Dula R, Bullock H, Sarubbi FA. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective? Infect Control Hosp Epidemiol. 2003;24:342–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Hayden MK, Lolans K, Haffenreffer K, et al. Chlorhexidine (CHG) and mupirocin susceptibility of methicillin-resistant Staphylococcus aureus (MRSA) isolates in the REDUCE-MRSA trial. J Clin Microbiol. 2016;54:2735–42Google Scholar
  42. 42.
    Fawley WN, Parnell P, Hall J, Wilcox MH. Surveillance for mupirocin resistance following introduction of routine peri-operative prophylaxis with nasal mupirocin. J Hosp Infect. 2006;62:327–32.CrossRefPubMedGoogle Scholar
  43. 43.
    Hill RL, Casewell MW. The in-vitro activity of povidone-iodinecream against Staphylococcus aureus and its bioavailability in nasal secretions. J Hosp Infect. 2000;45:198–205.CrossRefPubMedGoogle Scholar
  44. 44.
    Phillips M, Rosenberg A, Shopsin B, et al. Preventing surgical site infections: a randomized, open-label trial of nasal mupirocin ointment and nasal povidone-iodine solution. Infect Control Hosp Epidemiol. 2014;35:826–32.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Bebko SP, Green DM, Awad SS. Effect of a preoperative decontamination protocol on surgical site infections in patients undergoing elective orthopedic surgery with hardware implantation. JAMA Surg. 2015;150:390–5.CrossRefPubMedGoogle Scholar
  46. 46.
    Vernon MO, Hayden MK, Trick WE, et al. Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci. Arch Intern Med. 2006;166:306–12.CrossRefPubMedGoogle Scholar
  47. 47.
    Bleasdale SC, Trick WE, Gonzalez IM, et al. Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med. 2007;167:2073–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Popovich KJ, Hota B, Hayes R, et al. Effectiveness of routine patient cleansing with chlorhexidene gluconate for infection prevention in the medical intensive care unit. Infect Control Hosp Epidemiol. 2009;30:959–63.CrossRefPubMedGoogle Scholar
  49. 49.
    Milstone AM, Elward A, Song X, et al. Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial. Lancet. 2013;381:1099–106.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Septimus EJ, Hayden MK, Kleinman K, et al. Does chlorhexidine bathing in adult intensive care units reduce blood culture contamination? A pragmatic cluster-randomized trial. Infect Control Hosp Epidemiol. 2014;35(Suppl 3):S17–22.CrossRefPubMedGoogle Scholar
  51. 51.
    Derde LP, Cooper BS, Goossens H, et al. Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Infect Dis. 2014;14:31–9.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Kassakian SZ, Mermel LA, Jefferson JA, et al. Impact of chlorhexidene bathing on hospital-acquired infections among general medical patients. Infect Control Hosp Epidemiol. 2011;32:238–43.CrossRefPubMedGoogle Scholar
  53. 53.
    Bode LG, Kluytmans JA, Wertheim HF, et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med. 2010;362:9–17.CrossRefPubMedGoogle Scholar
  54. 54.
    Schweizer ML, Hsiu-Yin C, Septimus E, et al. Association of a bundled intervention with surgical site infections among patients undergoing cardiac, hip, or knee surgery. JAMA. 2015;313:2162–71.CrossRefPubMedGoogle Scholar
  55. 55.
    Patel PA, Schora DM, Peterson KE, et al. Performance of the Cepheid Xpert(R) SA nasal complete PCR assay compared to culture for detection of methicillin-sensitive and methicillin-resistant Staphylococcus aureus colonization. Diag Microbiol Infect Dis. 2014;80:32–4.CrossRefGoogle Scholar
  56. 56.
    Jeyaratnam D, Whitty CJ, Phillips K, et al. Impact of rapid screening tests on acquisition of meticillin resistant Staphylococcus aureus: cluster randomised crossover trial. BMJ. 2008;336:927–30.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Courville XF, Tomek IM, Kirkland KB, et al. Cost-effectiveness of preoperative nasal mupirocin treatment in preventing surgical site infection in patients undergoing total hip and knee arthroplasty: a cost-effectiveness analysis. Infect Control Hosp Epidemiol. 2012;33:152–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Young LS, Winston LG. Preoperative use of mupirocin for the prevention of healthcare-associated Staphylococcus aureus infections: a cost-effectiveness analysis. Infect Control Hosp Epidemiol. 2006;27:1304–12.CrossRefPubMedGoogle Scholar
  59. 59.
    Gidengil CA, Gay C, Huang SS, et al. Cost-effectiveness of strategies to prevent methicillin-resistant Staphylococcus aureus transmission and infection in an intensive care unit. Infect Control Hosp Epidemiol. 2015;36:17–27.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Nair R, Perencevich EN, Blevins AE, et al. Clinical effectiveness of mupirocin for preventing Staphlylococcus aureus infections in non-surgical settings: a meta-analysis. Clin Infedt Dis. 2016;62:618–30.CrossRefGoogle Scholar
  61. 61.
    Calfee DP, Salgado CD, Milstone AM, et al. Strategies to prevent methicillin-resistant Staphylococcus aureus transmission and infection in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35:S108–32.CrossRefPubMedGoogle Scholar
  62. 62.
    Lee AS, Macedo-Vinas M, Francois P, et al. Impact of combined low-level mupirocin and genotypic chlorhexidine resistance on persistent methicillin-resistant Staphylococcus aureus carriage after decolonization therapy: a case-control study. Clin Infect Dis. 2011;52:1422–30.CrossRefPubMedGoogle Scholar
  63. 63.
    Batra R, Cooper BS, Whiteley C, et al. Efficacy and limitation of a chlorhexidine-based decolonization strategy in preventing transmission of methicillin-resistant Staphylococcus aureus in an intensive care unit. Clin Infect Dis. 2010;50:210–7.CrossRefPubMedGoogle Scholar
  64. 64.
    Hetem DJ, Bootsma MCJ, Bonten JM. Preventionb of surgical site infections: decontamination with mupirocin based preoperative screening for Staphylococcus aureus carriers or universal decontamonation? Clin Infect Dis. 2016;62:631–6.CrossRefPubMedGoogle Scholar
  65. 65.
    Murthy A, De Angelis G, Pittet D, et al. Cost-effectiveness of universal MRSA screening on admission to surgery. Clin Microbiol Infect. 2010;16:1747–53.CrossRefPubMedGoogle Scholar
  66. 66.
    Lee BY, Tsui BY, Bailey RR, et al. Should vascular surgery patients be screened preoperatively for methicillin-resistant Staphylococcus aureus? Infect Control Hosp Epidemiol. 2009;30:1158–65.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Clancy CJ, Bartsch SM, Nguyen MH, et al. A computer simulation model of the cost-effectiveness of routine Staphylococcus aureus screening and decolonization among lung and heart-lung transplant recipients. Eur J Clin Microb Infect Dis. 2014;33:1053–61.CrossRefGoogle Scholar
  68. 68.
    Lee BY, Wiringa AE, Bailey RR, et al. The economic effect of screening orthopedic surgery patients preoperatively for methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol. 2010;31:1130–8.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Lee BY, Song Y, McGlone SM, et al. The economic value of screening haemodialysis patients for methicillin-resistant Staphylococcus aureus in the USA. Clin Microbiol Infect. 2011;17:1717–26.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Nelson RE, Samore MH, Smith KJ, et al. Cost-effectiveness of adding decolonization to a surveillance strategy of screening and isolation for methicillin-resistant Staphylococcus aureus carriers. Clin Microbiol Infect. 2010;16:1740–6.CrossRefPubMedGoogle Scholar
  71. 71.
    Bloom BS, Fendrick AM, Chernew ME, Patel P. Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients: a decision analysis. Am J Kidney Dis. 1996;27:687–94.CrossRefPubMedGoogle Scholar
  72. 72.
    Huang SS, Septimus E, Avery TR, Lee GM, Hickok J, Weinstein RA, Moody J, Hayden MK, Perlin JB, Platt R, Ray GT. 2014Cost savings of universal decolonization to prevent intensive care unit infection: implications of the REDUCE MRSA trial. Infect Control Hosp Epidemiol. 2014;35(Suppl 3):S23–31.CrossRefPubMedGoogle Scholar
  73. 73.
    Robotham JV, Deeny SR, Fuller SR, et al. Cost effectiveness of national mandatory screening of all admissions to English National Health Service hospitals for meticillin-resistant Staphylococcal aureus: a mathematical modelling study. Lancet Infect Dis. 2016:348–59.Google Scholar
  74. 74.
    Ziakas PD, Zacharioudakis IM, Zervou FN, Mylonakis E. Methicillin-resistant Staphylococcus aureus prevention strategies in the ICU: a clinical decision analysis. Crit Care Med. 2015;43:382–93.CrossRefPubMedGoogle Scholar
  75. 75.
    Active Bathing to Eliminate Infection (ABATE Infection) Trial. https://clinicaltrials.gov/ct2/show/NCT02063867. Last accessed 27 Mar 2016.

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Infection Prevention and EpidemiologyClinical Services Group, HCANashvilleUSA
  2. 2.Internal MedicineTexas A&M Health Science Center College of MedicineHoustonUSA

Personalised recommendations